Belantamab
(Anti-human BCMA mAb, human IgG1-Kappa)
Catalog No.: PC-Ab1042Not For Human Use, Lab Use Only.
B-cell maturation antigen (BCMA) is a cell-surface receptor of the tumour necrosis superfamily required for plasma cell survival. BMCA is universally detected on patient-derived myeloma cells and has emerged as a selective antigen to be targeted by novel treatments in multiple myeloma. Belantamab mafodotin (belamaf.
B-cell maturation antigen (BCMA) is a cell-surface receptor of the tumour necrosis superfamily required for plasma cell survival. BMCA is universally detected on patient-derived myeloma cells and has emerged as a selective antigen to be targeted by novel treatments in multiple myeloma. Belantamab mafodotin (belamaf; BLENREP, GSK2857916) is a first-in-class antibody–drug conjugate (ADC) that targets B-cell maturation antigen (BCMA).
Physicochemical Properties
M.Wt
Formula
Human IgG1-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
